How To Treat A Mental Illness

Transcription

1 Ira David Glick, MD Pacific Research Partners, LLC 1611 Telegraph Avenue, Suite 100 & Suite 1550 Oakland, CA CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) Fax (208) AFFILIATIONS: Collaborative Neuroscience Network, LLC Valley View Street, Suite 3 Garden Grove, CA Collaborative Neuroscience Network, LLC Redondo Avenue, Suite 500 Long Beach, CA Collaborative Neuroscience Network, LLC S. Vermont Avenue, Suite F-100 Torrance, CA Stanford University Medical Hospital EDUCATION: 1957 B.S., Dickinson College, Carlisle, Pennsylvania 1961 M.D., New York Medical College INTERNSHIPS AND RESIDENCIES: Candidate, New York Psychoanalytic Institute, New York, NY Rotating Internship, Beth Israel Hospital, New York, NY Psychiatry Residency: First Year Resident, Hillside Hospital, Glen Oaks, New York Second Year Resident, Mt. Zion Hospital, San Francisco, CA Chief Resident, Hillside Hospital 12/31/

2 LICENSURE: New York State Medical License 1963 Diplomate of the National Board of Medical Examiners 1963 California State Medical License - (G 9084) 1968 Diplomate of the American Board of Psychiatry and Neurology 1980 Mental Health Administrator, Commission on Certification in Administrative Psychiatry of the American Psychiatric Association Maryland Medical License (License number available on request) PROFESSIONAL EXPERIENCE: Principal Investigator, Present Pacific Research Partners, Oakland, CA Professor Emeritus, Psychiatry, June 2010 Present Director, Schizophrenia Research Clinic, 1993 June 2010 Director of Inpatient & Partial Hospitalization Services, Stanford University School of Medicine & Stanford University Hospital Acting Deputy Chief of Staff and Chief of Psychiatry, Veterans Administration Hospital, Palo Alto, CA Associate Medical Director, Payne Whitney Clinic, Department of Psychiatry, The New York Hospital Senior Science Advisor to the Director, National Institute of Mental Health, Rockville, MD Director, Inpatient Services, Director, of the Family Therapy Program, Director, Outpatient Department, Cornell Medical Center Chief, Clinical Research Ward, (Renamed the Inpatient Treatment & Research Service, 5/1/75) Director, Medical Student Education, Langley Porter Neuropsychiatric Institute and Dept. of Psychiatry, School of Medicine University of California, San Francisco Service Record: Captain, Army of the United States, Chief, Psychiatry Service, U.S. Army Hospital Specialized Treatment Center, Fort Gordon, Georgia 12/31/

3 PROFESSIONAL EXPERIENCE (continued): Staff Psychiatrist and Research Associate, Hillside Hospital, Glen Oaks, New York INVESTIGATOR EXPERIENCE: INTEREST: Adolescent Psychiatry Anxiety Bipolar Disorder Depression Insomnia Mania Schizophrenia ADHD Alzheimer s Disease Anxiety Dementia Multiple Sclerosis Post Traumatic Stress Disorder (PTSD) Sleep Disorders CLINICAL TRIAL EXPERIENCE: Addiction A Phase III, multi center, double blind, placebo controlled, randomized withdrawal study to evaluate the maintenance and efficacy of XXX in adults aged with moderate to severe binge eating A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder A Phase III, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adults Aged Years with Moderate to Severe Binge Eating Disorder Bipolar Disorders A Phase III, 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX as an Adjunctive Therapy to Treatment-as- Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects 12/31/

4 CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX Tablet for Sublingual Administration XXX in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects Who Are on Lithium or Valproate A Phase IIIb, Double-Blind, Placebo-Controlled Trial of XXX in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder Depression A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy A Phase III, Open-Label Extension Study to Assess the Safety and Tolerability of Treatment With XXX in Patients Who Have Completed Study XXX A Phase II, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of XXX in the Adjunctive Treatment of Subjects with Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment A Phase III Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX in Major Depressive Disorder A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of XXX on Cognitive Dysfunction in Adult Subjects with Major Depressive Disorder A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of XXX as Monotherapy Treatment in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of XXX Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment 12/31/

5 CLINICAL TRIAL EXPERIENCE (continued): A Phase III,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of XXX in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD) A Phase III,, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects With Major Depressive Disorder A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible- Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX Treatment. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy 12/31/

6 CLINICAL TRIAL EXPERIENCE (continued): Schizophrenia An Exploratory, Multicenter, Open-label, Flexible-dose XXX Trial in the Treatment of Adults with Early-Episode Schizophrenia A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia A Phase II, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Schizophrenia to Mitigate or Prevent XXX -Induced Weight Gain A Phase III, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of XXX in Subjects with Acute Exacerbation of Schizophrenia A Phase II, partial-blind, multi-center extension study to evaluate the long-term safety and health outcomes of XXX in subjects who completed Study XXX (Long-Term Safety and Efficacy of XXX in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study XXX) A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A Randomized, Double-blind, Placebo-controlled, Parallel, 12 Week, Phase III Study of 2 Doses of XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy A Phase III Multicenter 40-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy A Phase IIb, 12 week randomized, double-blind, placebo-controlled, parallel group, multiple dose, proof-of-concept study to evaluate the effects of XXX on cognition in stable schizophrenia patients 12/31/

7 CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Non-smokers A Phase III, Randomized, Multicenter, Double-Blind, Non-inferiority Study of XXX 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of XXX on Schizophrenia Negative Symptoms A Multicenter, Open-label, Single-arm Flexible Dose (20-80 mg Twice Daily, Phase III Study of XXX in Outpatients who complete (rollover) a previous XXX Study and a Study duration of up to 2 years after US XXX Monotherapy Launch A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on XXX on Schizophrenia Negative Symptoms A Phase III, Short-term, Muticenter, Placebo-controlled, Randomized Withdrawal Study of XXX Monohydrate with DSM-IV-TR Schizophrenia A Phase III, Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with XXX Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible- Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia A Multicenter, Double-Blind Comparison of XXX and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia 12/31/

8 CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible- Dose, Open-label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX 12/31/

9 FUNDED RESEARCH ACTIVITIES: G.D. Searle Research Grant for the study Pseudopregnancy Treatment of Periodic Psychiatric Illness National Institute of Mental Health Grant for the project MH Short vs. Long Psychiatric Hospitalization: A Controlled Study $133,000, Supplement $ 25, Lederle Research Grant for the study XXX Treatment in Schizophrenia Endo Research Grant for the study XXX vs. XXX: Double Blind Investigation of the Treatment of Acute Schizophrenia National Institute of Mental Health Grant for Medical Student Psychiatric Education, $395, Vice Chancellor's Advisory Committee on Instructional Improvements Grant, UCSF, for project Effectiveness and Efficiency in Small Group Teaching with Mary Malloy, MD $ 1, National Institute of Mental Health - Biomedical Research Support Grant for the study Inpatient Family Intervention: A Controlled Study $ 15, National Institute of Mental Health Contract -to develop a Model Psychopharmacology Curriculum for Psychiatric Residency Training (with David Janowsky MD) under the auspices of the American College of Neuropsychopharmacology $ 4, National Institute of Mental Health Grant for project Inpatient Family Intervention: Evaluation of Practice, $180, National Institute of Mental Health, Cooperative Clinical Agreement Award for the project, Treatment Strategies in Schizophrenia, $863, Supplement $104, Competitive Renewal $688, Supplement $30,000 12/31/

10 FUNDED RESEARCH ACTIVITIES (continued): 1987 XXX Research Award for the project, Delivery and Compliance to Good Medical Treatment $ 20, XXX Grant for the study, XXX in the Treatment of the Negative Symptoms of Schizophrenia National Institute of Mental Health Grant, Marital Treatment for Bipolar Disorder Patients, Co-Principal Investigator with John Clarkin, PhD, P.I. $520, (Cornell) XXX Research Grant for the study: XXX in the & Prevention of Mania 1993 (Stanford) 1992 XXX Research Grant for the study: XXX for the Treatment of Schizophrenia and Schizoaffective Disorder 1992 (Cornell) XXX Research Grant for the study: The Safety and Efficacy of XXX in Schizophrenic Patients 1993 (Stanford) A Double-Blind, Haldol-Referenced, Placebo-Controlled Study 1993 Pharmacologic Medication Discovery & Development Project (PMDDP) Supported by XXX $10, XXX for the Study, Treatment of Adolescent Depression with XXX 1993 XXX Grant for the study, Safety and Efficacy of XXX in the Prevention of Mania in Patients With Bipolar Disorder 1995 XXX Unrestricted grant to develop a Model Psychopharmacology Curriculum for Residents (Committee Chair) under the auspices of the American Society of Clinical Psychopharmacology 1995 XXX Research Grant for the study, XXX versus XXX in the Treatment of Schizophrenia and other Psychotic Disorders 1995 XXX Grant for the study, Dose-Response Study in the Treatment of Negative Symptoms of Schizophrenia with XXX $50,000 12/31/

11 FUNDED RESEARCH ACTIVITIES (continued): 1995 XXX Research Grant for the study, A Comparative Cost Effectiveness Study of XXX and Usual Care versus XXX and Usual Care in the Treatment of Bipolar Disorder 1996 XXX Research Grant for the study, A Multi-center, Open, Randomized Comparison of and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder 1997 XXX Research Grant for the study, A Multi-center, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients 1997 XXX Research Grant for the study, A Phase III Double-Blind Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control 1998 XXX Corporation, A Prospective, Randomized, International, Parallel-group Comparison of XXX vs. XXX in the Reduction of Suicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are at Risk for Suicide 1998 Research Grant for the investigator initiated study, XXX vs XXX for the Long-Term Treatment of Schizophrenia and Schizoaffective Disorder with Marder S. $100, XXX, The Acute and Long-Term Efficacy of XXX in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with XXX 1998 XXX Pharmaceuticals, A Multi-Center, Placebo Controlled Double Blind Study Comparing the Safety and Efficacy of XXX with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care XXX, XXX vs. Placebo in the Treatment of Subjects with Schizophrenia or Schizoaffective Disorder 2009 Educational Outreach Initiative Grant $5, XXX, A Multi-center, Double-Blind, Randomized, Active-Controlled, Study to Evaluate the Long-term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia 12/31/

12 FUNDED RESEARCH ACTIVITIES (continued): 2008 Schizophrenia Trials Network associated with NIMH Contract XXX Comparison of Optimal Antipsychotic Treatment for Schizophrenia (COATS: A Pilot Study) XXX in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS: A Pilot Study) 2008 Keeping Up With Advances in Psychopharmacology in the New Millenium, four lectures at medical schools in Israel, supported by the Sarlo Fund and the Ingrid D. Tauber Philanthropic Fund from the Jewish Community Endowment Fund, San Francisco, June, $4, XXX, Validation of the Reasons for Antipsychotic Discontinuation/Continuation Questionnaire (RAD-Q) and Interview (RAD-I) 2007 A Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral XXX in Adolescents with Schizophrenia XXX, A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect Of XXX Versus XXX In Patients With Schizophrenia Using the XXX 2007 American College of Neuropsychopharmacology, ACNP Public Outreach Initiative Schizophrenia Education Day. (also supported by XXX) $5, XXX, An Open-Label Study of Equetro in Outpatients with Aggressive Symptoms & Behavior (investigator initiated study) $125, XXX, A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 16-week Study of XXX Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to XXX Monotherapy XXX, A Multi-center, Double-Blind, Flexible-Dose, 6-month Trial Comparing the Efficacy and Safety of XXX in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia CAMP (Foundation for NIH), Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to XXX vs. XXX $116,900 12/31/

13 FUNDED RESEARCH ACTIVITIES (continued): 2005 American College of Neuropsychopharmacology, ACNP Public Outreach Program $ 5, XXX vs. XXX Double Blind. (investigator initiated Study) $120, XXX, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of XXX in the Treatment of Schizophrenia Co-Investigator of a XXX Grant for a project Fostering Collaboration Through Clinical Education: A Clinical Neurosciences Seminar, Clinic and Curriculum Series in Child Psychiatry and Pediatric Neurology (with Joshi SV, Chang KD and Hahn J) XXX Education Fund 2004 XXX, Comparison of Atypicals for First Episode (CAFE) $30, XXX, The Treatment of Schizophrenia and OCD Symptomatology with XXX (investigator initiated study). $80, XXX, Efficacy and Weight Reduction Effects of XXX in Stabilized Patients with Schizophrenia and Weight Associated with Atypical Antipsychotics (investigator initiated study with Reaven). $105, XXX, An Open-Label Follow-Up Study of the Long-Term Safety of XXX in Patients with Psychosis Pfizer, Zodiac International Schizophrenia Study to Compare the Cardiovascular Safety of XXX and XXX XXX, A 12 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Evaluation of XXX as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patient with Schizophrenia or Schizoaffective Disorder 2001 XXX, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Flexible Doses of XXX Versus XXX In the Treatment of Patients with Treatment-Resistant Schizophrenia 12/31/

14 FUNDED RESEARCH ACTIVITIES (continued): 2000 National Institute of Mental Health, sub-contract, Comparative Effectiveness of Antipsychotic Medications in Patients with Schizophrenia CATIE. Human Genetics Initiative $550, Development of a Model Psychopharmacology Curriculum for Psychiatric Residents. (through the American Society of Clinical Psychopharmacology) Supported in part by XXX $15,000 EDITORIAL AND ADVISORY BOARDS: Family Process 1981 Journal of Clinical Psychopharmacology 1981 Contemporary Family Therapy - An International Journal The Journal of Family Therapy (England) Board of Advisors, Dickinson College The Journal of Family Psychotherapy National Council of Advisors on Development and External Affairs, UCSF 1989 Progress in Neuropsychology and Biological Psychiatry Advisory Board, MultiMedia Reviews in Psychiatry, Massachusetts General Hospital Board Member, The National Mental Health Project 1993 Sertindole Advisory Board,, Neuroscience Venture, Abbott Laboratories Gralnick Foundation Awards Committee 1996 CNS Science Advisory Board, Wyeth Ayerst Pharmaceutical Advisory Board, Janssen Pharmaceutica and Research Foundation Advisory Board, Institute for Healthcare Quality, Minneapolis 1997 Advisory Board, Zeneca Pharmaceuticals 12/31/

15 EDITORIAL AND ADVISORY BOARDS (continued): 1998 Advisory Board, Otsuka Pharmaceuticals 1999 Advisory Board, Hoechst Marion Roussel (Aventis) 1999 Advisory Board, NPSP Pharmaceuticals Bipolar Clinical Advisory Board, Boca Raton 2001, 2005 Advisory Board, Pfizer (Geodon) Pharmaceuticals 2001 Board of Directors, National Foundation for Depressive Illness, Inc. 2002, 04,05 Advisory Board, Shire Pharmaceuticals 2002, 03,04,05 Advisory Board, Bristol-Myers Squibb California Neuroscience Advisory Board Editorial Board, The Journal of Clinical Psychiatry Editorial Board, The Physician and Sports Medicine 2009 Advisory Board, Pfizer. Anxiety Disorders AWARDS: Skull & Key Award: Dickinson College. Given yearly to College's most outstanding freshman 1959 National Foundation Medical Student Fellowship, Dept. of Physical Medicine & Rehabilitation, New York Medical College (Summer) 1960 National Institute of Mental Health Research Training Grant, Dept. of Psychiatry, New York Medical College (Summer) 1961 Stephen P. Jewett Award : Dept. of Psychiatry, New York Medical College. One award given each year for proficiency in psychiatry to a fourth year medical student 1968 Army Commendation Medal: U.S. Army Hospital, Ft. Gordon, Georgia Career Teacher in Psychiatry: National Institute of Mental Health, MH Dept. of Psychiatry Nominee for the Kaiser Award for Excellence in Teaching, and the UCSF Budget Committee Award for Special Recognition of Distinction in Teaching 12/31/

16 AWARDS (continued): 1979 American Journal of Nursing, 1979, Books of the Year Award, presented for "Psychiatric Hospital Treatment for the 1980's" Consultant, Psychiatric Education Branch of the National Institute of Mental Health Ad Hoc Reviewer for the Psychosocial & Biobehavioral Treatments Subcommittee of the Treatment Development and Assessment Research Review Committee, NIMH 1982 Member, Special Review Committee on Depression, ADAMHA, NIMH (July) 1987 Fulbright Research Scholar, Japan, (January through July) Research Fellowship, the Japanese National Institute of Mental Health, Itchikawa, Japan, (January through July) 1987 The American Psychiatric Association and Psychiatric Institute of America (PIA) Award for Hospital Psychiatric Research, awarded annually for research in the field of hospital psychiatric treatment The Best Doctors in America 1990 The Seymour D. Vestermark Award, awarded annually "to recognize leadership & creativity in psychiatric education, "by the American Psychiatric Association, (given to the ACNP for a Model Curriculum in Psychopharmacology developed by a subcommittee which I co-chaired with David Janowsky, MD) 1990 Director's Award, National Institute of Mental Health 1991 The Association for Academic Psychiatry Psychiatric Education Award, Honorable Mention, awarded biannually for Innovative Educational Materials and Techniques, for the Model Curriculum in Psychopharmacology 1991 One of three recipients of Alumni Achievement Awards from New York Medical College 1991 Runner-up for The American Academy of Clinical Psychiatrists Clinical Research Award MacArthur Foundation Research Network on Depression 12/31/

17 AWARDS (continued): 1993 The Van Ameringen Award in Psychiatric Rehabilitation, awarded annually by American Psychiatric Association, in recognition of outstanding and sustained contributions to field of psychiatric rehabilitation in areas of research, service and education (in 1992, I was given Honorable Mention for this same award) 1994 The Gralnick Award, given annually by the American Psychological Foundation to a researcher whose work covers the psychosocial aspects of schizophrenia with an emphasis on the early stages of the disorder 1996 Association for Academic Psychiatry Annual 1997 Education Award for outstanding contributions as an educator, both in curriculum development and in presentation 2000 Annual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) of the APA, recognizes a member of NCPS who has made significant and exceptional contributions to the field of psychiatry Distinguished Contribution to Family Systems Research Award. This annual AFTA award recognizes an individual for outstanding research on subjects central to the field of family therapy Rockefeller Foundation Award for Residence at Bellagio, Italy, Summer Metzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA 2003 Fulbright Lecturing Award, India 2004 Excellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. In recognition of contributions to the educational mission of the school Nominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM 2005 First Annual Irma Bland Award for Excellence in Teaching Residents, given annually by the American Psychiatric Association to Departments of Psychiatry for outstanding and sustaining contributions made as a faculty Paul Hoch Distinguished Service Award for Contributions to the College, presented by the American College of Neuropsychopharmacology 12/31/

18 AWARDS (continued): 2006 Dickinson College Distinguished Alumni Award for Professional Achievement. This yearly award names alumni who have demonstrated outstanding accomplishment, as well as strength of character, in their professional and civic lives CINP 2006 Lundbeck Neuroscience Foundation Prize for Education in Psychiatry and Neurology, one award given every 2 years for education in psychiatry and neuroscience to an individual (or group) who has attained particularly valuable achievements in the field of postgraduate education in psychiatry and neuroscience The American College of Psychiatrists (ACP) Distinguished Service in Psychiatry Award, one award given each year to recognize distinguished achievements and leadership in the field of psychiatry The Association for Academic Psychiatry, Distinguished Life Fellow, given each year for mastery in a career dedicated to educational endeavors, demonstrated generativity by unselfishly guiding the next generation of academic psychiatrists, and engaged in passing on the traditions of the past to the next generation of academic psychiatrists National Alliance on Mental Illness (NAMI) exemplatory Psychiatrist Awards ACADEMIC APPOINTMENTS: Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine 2010 Emeritus Professor Professor of Psychiatry, Cornell University Medical College, New York, NY School of Medicine, University of California, San Francisco (UCSF): Assistant Clinical Professor of Psychiatry and of Obstetrics & Gynecology Career Teacher in Psychiatry of the National Institute of Mental Health at Langley Porter Neuropsychiatric Institute Associate Clinical Professor Professor of Psychiatry in Residence, School of Medicine Assistant Clinical Professor of Psychiatry, Medical College of Georgia Instructor & Assistant Attending Psychiatrist, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University 12/31/

19 OTHER TRAINING: Dept. of Research, Hillside Hospital: Seminar on Research Methods in Psychiatry, D. Klein, MD J. Starkweather, PhD, Dept. of Information Systems, UCSF: An Introduction to Computer Programming PL Dept. of Psychiatry, UCSF: Seminar on Supervision, R. Wallerstein, MD Dept. of Psychiatry, UCSF: Seminars on Models in Psychiatry, J. Ruesch, MD Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Course on Advanced Statistics, W. Hargreaves, PhD Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Advanced Statistics, 226- A & B, R. Elashoff, PhD and W. Hargreaves, PhD UCSF: Health Sciences Education Seminar, E. Rosinski, PhD 1972 Dept. of Anatomy, UCSF: Course on Cell Structure & Function, R. Long, PhD 1972 Dept. of Physiology, UCSF: Course, Endocrinology 101, C. Kragt, PhD 1972 Dept. of Business Administration, Philosophy of Management University of California, Berkeley Science, C. Churchman, PhD 1973 Cardiovascular Research Institute, UCSF: Group Practice in the Art of Teaching, N. Staub, MD Dept. of Psychiatry, Albert Einstein College of Medicine: Administrative Psychiatry & Mental Health Planning, S. R. Kaplan, M.D. COMMITTEES: University Of California, San Francisco, School of Medicine: Department of Psychiatry Committees: Administrative Planning Team, Langley Porter Institute Interdisciplinary Education Committee, Dept. of Psychiatry, School of Medicine Medical Student Education Committee, Dept. of Psychiatry, School of Medicine 1976 Ad Hoc Committee for Alexander Simon Award, Dept. of Psychiatry 1976 Subcommittee for Basic Curriculum, Residency Training, Dept. of Psychiatry Departmental Task Force on Revision of Medical Student Curriculum, Dept. of Psychiatry 12/31/

20 COMMITTEES (continued): Committee on Academic Affairs, Dept. of Psychiatry, School of Medicine, UCSF Staff Affiliate Review Committee, Langley Porter Institute Departmental Committee on Medical Student Education, Dept. of Psychiatry Review Committee for Appointments and Promotions of Regular Faculty, Dept. of Psychiatry Departmental Committee on Medical Student Education, Dept. of Psychiatry 1973 Building Committee, Langley Porter Institute 1972 Noon Conference Committee, Langley Porter Institute Residency Training Committee, Langley Porter Institute Residency Selection Committee, Langley Porter Institute 1970 Ad Hoc Committee on Outpatient Psychiatric Care, Dept. of Psychiatry Course Committee, Sophomore Psychiatry Course, Dept. of Psychiatry Ad Hoc Committee on Residency Training, Langley Porter Institute 1969 Annual Graduation and Departmental Meeting, Langley Porter Institute 1969 Course Committee, Freshman Psychiatry Course, Dept. of Psychiatry Chairman, Public Health and Safety Committees, Langley Porter Institute Research Committee, Clinical Research Ward, Langley Porter Institute School of Medicine Committees: Curriculum Committee Subcommittee on Evaluation Basic Clinical Course Operations Subcommittee1974; Acting Chairman, Screening and Promotions Committee Search Committee, Director of Psychiatric Nursing, Cornell University Medical College: Department of Psychiatry Committees Steering Committee Residency Training Committee Appointments and Promotions Committee Formulary Committee 1990 Task Force on Vertical Services Executive Committee Executive Committee Space Committee Fellowship Selection Committee Residency Training Committee Computer Committee Media Committee PGY IV Education Committee Inpatient Steering Committee 12/31/

21 COMMITTEES (continued): Family Therapy Planning Group, PGY II Education Committee Departmental Research Committee- Chairman, ; Residency Training Committee Fellowship Selection Committee Stanford University School Of Medicine: Departmental Committees Appointment & Promotions Chair, Credentials Committee, Chairman Residency Training Committee Executive Committee Hospital Committees UCSF/Stanford Merger - Brown & Toland Medical Group Mental Health Executive Committee Inpatient Management Committee Operations Improvement Committee Psychiatry Business Plan Committee Clinic Executive Committee Mentoring Jacob S. Ballon, M.D., American Psychiatric Institute for Research & Education REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES: American Medical Association American Psychiatric Association 1971 Fellow Foundations' Fund Board for Research in Psychiatry (Chair, ) 1999 Life Fellow 1999 Member, Committee on Research on Psychiatric Treatments 2003 Sub-committee on Antipsychotic Drugs & Diabetes Mellitus Northern California Psychiatric Society (NCPS) Committee on Awards Counselor-at-Large 12/31/

22 REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES (continued): American College of Psychiatrists Fellow 1996 Committee on Honorary Fellowships Society of Biological Psychiatry Resource Development Committee 1997 Task Force on the Future of SBP 2001 George N. Thompson Award Committee, Society of Biological Psychiatry American College of Neuropsychopharmacology 1973 & 1978 Scientific Associate Member Education and Training Committee, (Chair, ) 1984 Fellow Co-Chair, Committee to Develop a Model Curriculum in Psychopharmacology Committee on Problems of Public Concern Task Force on Coordinating Academic Industry & Government Efforts in Psychopharmacology 1989 & '96-98 Task Force on Psychotropic Drug Prescribing Privileges for Non-physicians Task Force on Scientific Misconduct Mentor, NIMH/Mead Johnson Minority Award Program Finance Committee (Chair, ) Constitution and Rules Committee (Chair, ) Education and Training Committee (Co-Chair, ) History Committee Public Information Committee 1973 Association for Academic Psychiatry, Charter Member Secretary 1983 Co-Chairman and Founder, Section on Residency Training Fellowship Committee 2008 Distinguished Life Fellow 1978 The Hastings Center-Institute of Society, Ethics and the Life Sciences 1978 American Family Therapy Academy Board of Trustees 1985 Committee on History of AFTA 1980 American Association of Psychiatric Administrators 12/31/

23 REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES (continued): 1982 Association for Clinical Psychosocial Research, Founding Member Steering Committee 1988 Fellow Group for the Advancement of Psychiatry, Committee on the Family 1991 Program Committee 1992 Ad hoc Committee to Develop Practice Guidelines 1989 Psychiatric Research Society 1990 Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) 2002 CINP Regional Committee for North America Academia, Medicine & Psychiatric Foundation 1992 Fellow American Society of Clinical Psychopharmacology, Founding Member Model Curriculum Committee, Chair 1995 Work Group, Interface with Government & Industry, Clinical Trials Committee Scientific Advisory Board Treasurer 2005 Co-chair, Joint ASCP-AADPRT Curriculum Project (with David Goldberg, MD) International Society for Sports Psychiatry, Founding Member 1993 Chair, Scientific Program 1993 Executive Board Chair, Nomination Committee 1997 West Coast College of Biological Psychiatry, Fellow 1998 Program Chair 1998 Pacific Rim College of Psychiatrists, Fellow VISITING PROFESSORSHIP & LECTURES: 1972 VP: Dept. of Psychiatry, School of Medicine, University of San Marcos, Lima, Peru, (August) 1) Teaching of Psychiatry to Medical Students 2) Family Therapy Today Distinguished Lecturer, Lederle Pharmaceutical Co 12/31/

24 VISITING PROFESSORSHIP & LECTURES (continued): 1979 VP: Dept. of Psychiatry, College of Medicine, University of Arizona, Health Science Center, Tucson, Arizona 1980 Gary N. Spero Community Mental Health Memorial Lecture Series, "The Family Model in Inpatient and Day Hospital Settings," Maimonides Medical Center, Brooklyn 1980 VP: Dept. of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut 1981 VP: Maudsley Hospital, Tavistock Clinic and Hospital for Sick Children, London 1) "The Family Model in an Inpatient Setting", Seminar on Hospital Psychiatry,Mental Health Workers, Great Britain 2) "Family Therapy and Hospitalization", Tavistock Clinic 3) "Family Research", Marlborough Hospital 4) "Family Research", Grand Rounds, Hospital for Sick Children 5) "Indications and Contraindications for Family Therapy", The Family Institute of London 1982 Keynote Address, "Guidelines for Family Therapy," as part of a continuing education course entitled "Clinical Techniques for the Practice of Family Therapy," sponsored by the Dept. of Psychiatry, Long Island Jewish- Hillside Medical Center Visiting Faculty Program, Mead Johnson Pharmaceutical Co VP: Dept. of Psychiatry, University of California, San Diego 1983 VP: Dept. of Psychiatry, College of Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 1984 Schweppes Visiting Professor, The Menninger Clinic, Topeka 1985 VP: Dept. of Psychiatry, University of Wisconsin Medical School, Madison, "The Shrinking of Hospital Psychiatry" 1985 VP, Dept. of Psychiatry, Medical University of South Carolina, Charleston 1) Grand Rounds, "Inpatient Family Intervention - A Controlled Study" 2) Inge Taylor Memorial Lecture, "Why Don't Patients Receive Appropriate Psychiatric Treatment?" 3) All Day Seminar with Psychiatry Residents, "Theory & Practice of Integrative Psychiatry" 12/31/

25 VISITING PROFESSORSHIP & LECTURES (continued): 1985 VP: Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Dept. of Psychiatry, "The Family Model: Does It Have Anything to Offer for the Treatment of Affective Disorders?" 1985 VP: Fairfield Hills Hospital, Newtown, Connecticut, "Treating the Hospitalized Patient and Their Family" 1986 VP: Dept. of Psychiatry, School of Medicine, University of Verona, Italy, Jan- Jun 1990 Visiting Lecturer Series, "Effectiveness in Psychiatric Care," New Jersey College of Medicine and Dentistry, Newark 1990 Invited Speaker, "What a Psychiatric Hospital Can and Cannot Do: A Review of Efficacy Studies." At a conference, "The Role of the Mental Hospital in the 21st Century," sponsored by the London Psychiatric Hospital, Ontario, Canada 1990 Invited Lecture, "New Wine in New Bottles: The Changing Role of Psychiatric Hospitals for Patients and Their Families," at The Sheppard Pratt National Symposium on Schizophrenia, Baltimore 1991 Academic Lecture: "New Models for the Treatment of the Chronically Mentally Ill,"Annual Meeting of the Ontario Psychiatric Association, Toronto (February) 1991 Invited Lecture: "A Survival Guide for the Family of the Borderline Patient (and Vice Versa)," New Approaches to the "Borderline Syndrome," Sixth Tokyo Institute of Psychiatry International Symposium, Tokyo, Japan (November) 1993 VP & Invited Lecture: University Institutions of Psychiatry, Geneva, School of Medicine, University of Geneva, Switzerland and Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder seen in Europe, Asia and the U.S. United States" (April) 1993 VP: Institute of Clinical Psychiatry, School of Medicine, University of Pisa, Pisa, Italy, with Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States" 1993 Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Dept. of Psychiatry, Second School of Medicine, Naples, Italy (April) 12/31/

26 VISITING PROFESSORSHIP & LECTURES (continued): 1993 Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Institute of Clinical Psychiatry and the Dept. of Psychiatry, School of Medicine, Verona, Italy Academic Lecture: "Combining Medications with Psychosocial and Rehabilitation Strategies for the 1990's," 2nd Annual Psychopharmacology Clinical Day, Department of Psychiatry, University of Toronto, Toronto (October) Distinguished Lecturer, Professors of Psychiatry Series: New Strategies of Treatment for Axis I Disorders, VP, Department of Psychiatry, School of Medicine and Surgery, University of Bari, Italy, June. Keynote Speaker, Strategies of Intervention in Family Psychotherapy, First National Congress, Italian Society for Research and Interventions on the Family, Subsection of the Italian Psychiatric Society Keynote Address, Combination Therapy for the Treatment of Psychosis, Third Annual STEP Symposium, Improving the Prognosis of Psychotic Disorders (Schizophrenia Treatment & Evaluation Program), University of North Carolina at Chapel Hill, June, Keynote Address, Combination Therapy for the Treatment of Axis I Disorders, 1996 Taipai Mental Health Conference, Taipai, Taiwan, December VP, Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, March Award Lecture, Through the Golden Chalkboard: Reflections on the Teaching- Learning Process in Psychiatry, 1997 Annual Meeting of the Association of Academic Psychiatry, March, VP, Department of Psychiatry & Internal Medicine, St. Francis Medical Center, Pittsburgh, PA 1998 Principal Speaker, Lone Star : Society, The Family and Individual Identity, as part of the film series of the New Orleans Museum of Art and Department of Psychiatry LSU, entitled: Lights, Camera - Analysis, New Orleans, October, /31/

27 VISITING PROFESSORSHIP & LECTURES (continued): 1998 Keynote Speaker, New Treatments for Schizophrenia and Other Psychoses, at the National Satellite Symposium for the Argentine Psychiatric Society, Time for Change in the Treatment of Psychosis, Buenos Aires, Argentina, November, Principal Speaker, at the National Conference organized by the Uruguayan Ministry of Health,Uruguayan Society of Psychiatry and the Psychiatric Department of the School of Medicine in the National University, Montevideo, Uruguay, November 1998: New Atypical Antipsychotics and Their Indications Combining Medication and Psychotherapy for Axis I Disorders 1999 Visiting Professor, University Hospital Utrecht, The Netherlands, Summer Plenary lectures at the Schizophrenia Symposium, Eastern Idaho Regional Medical Center, Idaho Falls, ID, June, 1999: New Strategies for the Treatment of Axis I Disorders New Treatments for Schizophrenia 1999 Plenary Lecture, New Diagnositic Methods and Treatments for Schizophrenia: Turning the Treatment Corner at the Annual Meeting of the Canadian Psychopharmacologic Association, Halifax, June, Guest Lecture, The New Atypical Antipsychotics for New Indications, Annual Meeting, Korean Psychopharmacology Association, Korea, April, Visiting Professor, EPPIC Program, University of Melbourne, Melbourne, Australia, August, Invited Lecture, Novel Antipsychotics: What We ve Learned; What We Need to Know. CME course on Novel Antipsychotics, Case Western Reserve University School of Medicine, Cleveland, September, Visiting Professor, Family Studies Unit, National Institute Mental Health and Health Series (NIMHANS), Bangalore, India Combining Medication and Psychotherapy The New Model of Inpatient Psychiatry 2004 Inaugural Lecture, Gary N. Spero Memorial Lectureship, Schizophrenia and Psychosis: New Data, New (Combined) Treatments & New Controversies. Department of Psychiatry, Weill Medical College of Cornell University, New York, March, /31/

28 VISITING PROFESSORSHIP & LECTURES (continued): 2004 Visiting Professor, School of Medicine, University of Iowa Combining Medication and Psychotherapy for Axis I Disorders Schizophrenia: New Data and New Controversies 2005 At the Indonesian Society for Biological Psychiatry, Psychopharmacology and Sleep Medicine, Jakarta, Indonesia, February, Educational Symposia, The Teaching of Psychopharmacology: Circa 2005 Opening Plenary Lecture: Developing a Curriculum in Psychopharmacology 2005 Lecture: Developing a Curriculum in Psychopharmacology. Teaching Psychopharmacology: Substance, Methods, Science. Pre-Meeting: American Association of Directors of Psychiatric Residency Training, Tucson, AZ, March, Invited Lecture, Collaboration With Big Pharma, as part of the Stanford Summer Research Institute, entitled Careers in Geriatric Psychopharmacology. Stanford, CA, July, Invited Lecture. Using a Psychopharmacology Curriculum to Improve Training. Dept of Psychiatry, Cape Town Medical School, Cape Town, South Africa, April, Invited Lecture: CATIE Trial Results. At the Annual ECNP (European College of Neuropsychopharmacology) Meeting, Paris, September Invited Lecture: Clinical Antipsychotic Trials in Intervention Effectiveness. Oregon Psychiatric Association, Lake Oswego-Portland, OR, March Panel Discussion on CATIE trial, with W Hoffman, M Reaves, D Ruthven 2007 Invited Lecture: Teaching of Psychopharmacology Worldwide, consultant for the Lundbeck Institute, Copenhagen, Denmark, March Invited Participant: Joint Committee on Long-Term Management of Schizophrenia, Houston, April and October, 2007, Chaired by William Carpenter and John Newcomer Visiting Professor and Invited Lectures: The Teaching of Psychopharmacology: 2008, Department of Psychiatry, Sackler School of Medicine, Tel Aviv University and Sheba Medical Center, Tel Aviv, Israel Department of Psychiatry, Rappoport Faculty of Medicine Institute of Technology, Technion, Haifa, Israel 12/31/